AZITRA INC. NEW

Azitra presented a dermatology strategy at an investor conference based on modified skin bacteria, recombinant proteins and the licensed SIMPLE gene‑editing platform. Lead program ATR‑04 is in a randomized Phase I/II trial for rashes caused by EGFR inhibitors; initial safety data from cohort 1 are expected in Q3/Q4 2025. Other programs include the cosmeceutical ATR‑COSF (first human study planned for 2025) and the preclinical ATR‑01 for ichthyosis vulgaris; SIMPLE is intended to make genetic modification of bacteria more efficient and cost‑effective. The business is largely in the development stage and in the near term is highly dependent on the upcoming clinical safety and development milestones. » Plus sur de.investing.com

Azitra has regained compliance with the continued listing standards of the NYSE American and will be removed from the list of non-compliant issuers. NYSE Regulation confirmed that previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) have been remedied. Azitra remains subject to NYSE monitoring, and the exchange may consider stricter measures, including delisting, if further violations occur within 12 months. » Plus sur de.investing.com

Azitra has entered a securities purchase agreement with healthcare investors that will initially bring the company about $10.5 million and could provide up to an additional $20.9 million through option exercises. The company will issue 10,470 non-redeemable Series A convertible preferred shares and Series B and C warrants with an exercise price of $0.123; each preferred share converts, subject to shareholder approval, into approximately 8,129 common shares. The proceeds are intended to finance the development of filaggrin protein and peptide technologies for the cosmetics market; closing is expected on Friday and is subject to customary conditions. Azitra is trading at $0.14 (down 94% year-over-year), has a market capitalization of $2.21 million and reported a negative free cash flow of $10.93 million over the last 12 months, but shows a current ratio of 2.83. » Plus sur de.investing.com